- Home
- IBRX vs CNTA Comparison
IBRX vs CNTA Comparison
Compare IBRX & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CNTA
- Stock Information
- Founded
- IBRX 2014
- CNTA 2020
- Country
- IBRX United States
- CNTA United Kingdom
- Employees
- IBRX N/A
- CNTA N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- IBRX Health Care
- CNTA Health Care
- Exchange
- IBRX Nasdaq
- CNTA Nasdaq
- Market Cap
- IBRX 2.3B
- CNTA 2.3B
- IPO Year
- IBRX N/A
- CNTA 2021
- Fundamental
- Price
- IBRX $2.31
- CNTA $16.56
- Analyst Decision
- IBRX Strong Buy
- CNTA Strong Buy
- Analyst Count
- IBRX 5
- CNTA 10
- Target Price
- IBRX $10.20
- CNTA $30.56
- AVG Volume (30 Days)
- IBRX 9.0M
- CNTA 1.0M
- Earning Date
- IBRX 08-05-2025
- CNTA 08-12-2025
- Dividend Yield
- IBRX N/A
- CNTA N/A
- EPS Growth
- IBRX N/A
- CNTA N/A
- EPS
- IBRX N/A
- CNTA N/A
- Revenue
- IBRX $56,600,000.00
- CNTA $15,000,000.00
- Revenue This Year
- IBRX $629.94
- CNTA N/A
- Revenue Next Year
- IBRX $109.91
- CNTA N/A
- P/E Ratio
- IBRX N/A
- CNTA N/A
- Revenue Growth
- IBRX 4227.22
- CNTA 118.88
- 52 Week Low
- IBRX $1.83
- CNTA $9.60
- 52 Week High
- IBRX $7.48
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- IBRX 45.80
- CNTA 49.56
- Support Level
- IBRX $2.17
- CNTA $16.27
- Resistance Level
- IBRX $2.43
- CNTA $17.43
- Average True Range (ATR)
- IBRX 0.15
- CNTA 0.72
- MACD
- IBRX 0.00
- CNTA -0.20
- Stochastic Oscillator
- IBRX 27.92
- CNTA 16.40
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.